Prevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis

Helvaci, Nafiye; Eyupoglu, Nesrin Damla; Karabulut, Erdem; Yildiz, Bulent Okan

BACKGROUND AND OBJECTIVE: Obesity has been reported as a risk factor for adverse outcomes in COVID-19. However, available studies presenting data on obesity prevalence in patients with COVID-19 have conflicting results. The objective of this systematic review and meta-analysis is to evaluate the prevalence of obesity in these patients and to stratify the estimates by illness severity. METHODS: We performed a literature search with the use of Medline/PubMed and Google Scholar database from December 1, 2019 to June 27, 2020 and systematically reviewed studies reporting the number of obese patients with real-time reverse transcriptase polymerase chain reaction (rRT-PCR)-confirmed SARS-CoV-2 infection. RESULTS: Nineteen studies were identified. The pooled obesity prevalence rates were 0.32 (95% CI: 0.24–0.41) in hospitalized patients, 0.41 (95% CI: 0.36–0.45) in patients admitted to intensive care unit, 0.43 (95% CI: 0.36–0.51) in patients needing invasive mechanic ventilation (IMV), and 0.33 (95% CI: 0.26–0.41) in those who died. Obesity was associated with a higher risk for hospitalization [Odds ratio (OR): 1.3, 95% CI: 1.00–1.69; I(2) 52%, p = 0.05], ICU admission (OR: 1.51, 95% CI: 1.16–1.97; I(2) 72%, p = 0.002), and IMV requirement (OR: 1.77, 95% CI: 1.34–2.35; I(2) 0%, p < 0.001). The increase in risk of death did not reach statistical significance (OR: 1.28, 95% CI: 0.76–2.16, p = 0.35) which might be due to obesity survival paradox and/or unidentified factors. CONCLUSIONS: Our data indicate that obese subjects may be at higher risk for serious illness if infected and obesity may play a role in the progression of COVID-19.